Search Results - james+lambert

2 Results

Sort By:

Method for Treating Triple-Negative Breast Cancer Using AMPI-109

Breast cancer is the principle cause of cancer-related mortality in women. Gene profiling has clustered the disease into five major subtypes based on the expression of estrogen receptor (ER), progesterone receptor (PR), and human epi- dermal growth factor receptor 2 (HER2). Triple-negative breast cancers (TNBCs) comprise 15– 20% of all newly diagnosed...

Published: 12/1/2023 | Inventor(s): James Lambert, Hamid Gari, M. Scott Lucia, Rahul Ray, Ann Thor

Disease Areas Oncology

Category(s): Therapeutics

Derivatives of the small molecule anticancer drug, AMPI-109

Triple-negative breast cancer (TNBC) does not express the estrogen, progesterone or HER2 receptors and accounts for 10-20% of all breast cancer cases. TNBC lacks exploitable targets and tends to be higher grade than other breast cancers, making it difficult to develop effective treatments. PRL-3 is an oncogenic phosphatase that is overexpressed in many...

Published: 5/9/2023 | Inventor(s): James Lambert, Michael Wempe, M. Scott Lucia, Rahul Ray

Disease Areas Oncology

Category(s): Therapeutics